67-5

9/110

Figure 8　Last professor round (in a sterile ward)Figure 9　Thanks to my TEAM (the person in the left frame is the late Dr. Hiraku Takei)Juntendo University Professor of Hematology.” With this determination always in mind, I am glad to have had sense of accomplishment of “I achieved it as a professor” and reached the retirement age. This is attributed to the support kindly given to me from the course members and the whole staff related to hematology (Figure 8 and 9). I do not have anything except for feelings of gratitude for the “encounters that would never come again” with my “treasure” (every person I have met).Conflicts of interest: The author declares that there are no conflicts of interest 1) Komatsu N, Suda T, Sakata Y, et al: Megakaryocyto-poiesis in vitro of patients with essential thrombo-cythaemia: effect of plasma and serum on megakaryo-cytic colony formation. Br J Haematol, 1986; 64: 241-252. 2) Komatsu N, Suda T, Moroi M, et al: Growth and differ-entiation of a human megakaryoblastic cell line, CMK. Blood, 1989; 74: 42-48. 3) Komatsu N, Nakauchi H, Miwa A, et al: Establishment and characterization of a human leukemic cell line with megakaryocytic features: dependency on granu-locyte-macrophage colony-stimulating factor, inter-leukin 3, or erythropoietin for growth and survival. Cancer Res, 1991; 51: 341-348. 4) Komatsu N, Yamamoto M, Fujita H, et al: Establish-ment and characterization of an erythropoietin-depen-dent subline, UT-7/Epo, derived from human leukemia cell line, UT-7. Blood, 1993; 82: 456-464. 5) Komatsu N, Kunitama M, Yamada M, et al: Establish-ment and characterization of the thrombopoietin-de-pendent megakaryocytic cell line, UT-7/TPO. Blood, 1996; 87: 4552-4560. 6) Komatsu N, Kirito K, Shimizu R, et al: In vitro develop-ment of erythroid and megakaryocytic cells from a UT-7 subline, UT-7/GM. Blood, 1997; 89: 4021-4033. 7) Araki M, Yang Y, Masubuchi N, et al: Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasms. Blood, 2016; 127: 1307-1316. 8) Araki M, Yang Y, Imai M, et al: Homomultimerization of mutant calreticulin is a prerequisite for MPL binding and activation. Leukemia, 2019; 33: 122-131. 9) Masubuchi N, Araki M, Yang YJ, et al: Mutant calretic-ulin interacts with MPL in the secretion pathway for activation on the cell surface. Leukemia, 2020; 34: 499-509.413References